Form 4: Immunocore R&D Head Sells Shares Post-Option Exercise

Immunocore Holdings plc's Head of R&D, David M. Berman, executed pre-planned sales of ordinary shares following option exercises in mid-September 2025.

Summary

• David M. Berman, Head of R&D at Immunocore Holdings plc, reported transactions involving the company's ordinary shares.
• Transactions occurred on September 12, 2025, and September 15, 2025, under a Rule 10b5-1 trading plan adopted on May 9, 2025.
• On September 12, 2025, 22,532 ordinary shares were acquired through option exercise at a price of $17.46 per share.
• Immediately following, 21,232 ordinary shares were sold at a weighted average price of $35.63 (ranging from $35.22 to $36.21).
• An additional 1,300 ordinary shares were sold on September 12, 2025, at a weighted average price of $36.31 (ranging from $36.22 to $36.52).
• On September 15, 2025, 200 ordinary shares were acquired through option exercise at a price of $17.46 per share.
• Concurrently, 200 ordinary shares were sold at a weighted average price of $35.01 (ranging from $35.00 to $35.01).
• Following these transactions, the reporting person holds 198,639 employee share options with an exercise price of $17.46, exercisable immediately and expiring on September 12, 2028.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the transactions were conducted under a pre-planned 10b5-1 program, which mitigates concerns about opportunistic selling based on undisclosed material information. It primarily reflects an executive's personal financial planning and monetization of compensation.

Positives

• The Head of R&D realized a significant profit by selling shares at prices substantially higher than the option exercise price of $17.46.
• Transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned and systematic approach to stock sales rather than an immediate reaction to market conditions.

Negatives

• The transactions represent a reduction in the direct beneficial ownership of ordinary shares by a key executive, which could be perceived negatively by some investors.

Risks

• Insider selling, even when pre-planned, can sometimes lead to negative market sentiment or speculation regarding the company's future prospects, potentially impacting share price.

Future Outlook

No forward-looking statements or guidance regarding the company's performance or strategic direction are provided in this insider transaction report.

Management Comments

• The reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

Industry Context

This Form 4 filing details an individual executive's stock transactions and does not provide information relevant to broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the insider selling as a signal, though the 10b5-1 plan suggests it's a routine financial event rather than a reflection of company fundamentals. The profit realized by the executive could be seen as a positive indicator of stock performance from their perspective.

Key Dates

Recommendation

The filing is a routine Form 4 detailing an executive's pre-planned stock transactions under a Rule 10b5-1 plan. It does not contain new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The sales represent a monetization of executive compensation rather than a signal of fundamental weakness. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive company updates.

Keywords

Immunocore, IMCR, insider transaction, Form 4, stock sale, option exercise, David M. Berman, 10b5-1 plan, executive compensation